CTCX NASDAQ
Pittsburgh, PA 15203
US
Carmell Therapeutics Corporation (CTCX) specializes in the creation of plasma-based bioactive materials (PBMs) aimed at catalyzing tissue regeneration and repair following injury, illness, or the effects of aging. Their flagship product, CT-101, is a versatile accelerant with a dual focus. For orthopedic and dental applications, it's designed to enhance bone healing in cases such as tibia fractures, foot and ankle fusions, spinal fusions, and also serves as a dental bone graft substitute and bone void filler. Furthermore, CT-101 acts as a tissue healing accelerant, addressing conditions like androgenetic alopecia (pattern baldness) and persistent chronic wounds. Established in 2008, the company operates from its headquarters in Pittsburgh, Pennsylvania.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Anderson David W | P-Purchase | 739 | $3.94 | 2023-12-15 |
| Anderson David W | P-Purchase | 391 | $3.61 | 2023-12-14 |
| Anderson David W | P-Purchase | 1,087 | $5.57 | 2023-12-13 |
| Anderson David W | P-Purchase | 1,087 | $3.50 | 2023-12-12 |
| Anderson David W | P-Purchase | 1,087 | $3.53 | 2023-12-11 |